Here are some bullish reasons to consider investing in ResearchHub: $RSC
1. Growing Market and Unique Platform: 📈
2. Strong financial backing and Strategic investors 🧠
3. 1st mover advantage in #DeSci ☝️
4. High ranking among competitors 🏆
Check thread ⬇️
@ResearchHub has been shipping lots of new tools for funders.
The platform is now offering:
→ Endowments: earn Funding Credits on your $RSC holdings
→ Transparent peer review on proposals: know what experts think before you deploy capital
→ And now, a Funder Dashboard to track it all
More coming 👀
15 months ago, the first research grants were funded on ResearchHub.
Since then, 5.3M+ $RSC has been allocated to scientific research.
Science funding is moving onchain, and the pace is only accelerating.
Apply for funding or host a funding opportunity → https://t.co/nwM6PT7Bfz
The biology is ready. The researchers are ready. The funding hasn't kept up...until now.
@ResearchHub is offering $10k for research on reproductive longevity.
🧵
New Limit just raised $435 million. This is, in part, because they've had a massive breakthrough on reversing the age of the liver with their new brand of genetic reprogramming drugs.
For the first time, NewLimit's co-founder and president Jacob Kimmel details the company's breakthrough here.
We also get into the longevity and bio-tech fields more broadly to explain where aging science and AI are heading.
If nothing else, come to see some mice get drunk.
The Core Memory podcast is available wherever you pod, and I'll put the YouTube link down below in the replies.
Our show is sponsored by Brex and SendCutSend. They are both wise and benevolent.
Timestamps
0:00 Intro
3:50 What Is Epigenetic Reprogramming?
7:16 Growing a Whole Animal From One Old Cell
13:06 Meet Ambrosia, the AI Hunting for Youth
22:44 $435 Million and the Race to Human Trials
29:26 The Drunk Mice That Skip the Hangover
36:48 Inside the First Human Trial
43:14 Will There Ever Be a Hangover Pen?
49:39 Beyond the Liver: The Delivery Problem
1:03:27 Answering the Skeptics
1:12:42 Will OpenAI Become a Drug Company?
1:23:53 The Health Story Bigger Than AI?
1:35:00 How Far Behind Is the US vs China?
1:53:10 Can We Build Computers From Neurons?
The institutions, infrastructure, and capital behind science are being reimagined.
Catalyst NYC brings together researchers and funders to explore what’s working, what’s next, and where the opportunities lie.
We’ll be discussing:
→ Alternative funding models
→ Open science infrastructure
→ Where philanthropy and venture capital meet research
→ How discoveries move from the lab to real-world impact
And much more. Full agenda coming soon.
📅 July 11
📍 NYC
#CatalystNYC is invite-only.
Request an invitation: https://t.co/gj21WTmFf3
Since January 2025, ResearchHub has deployed over $1.5M in research funding to scientists worldwide.
We just redesigned our funding page to make it even easier for funders and researchers to connect.
Take a look ↓ https://t.co/BLp1KaeS5s
Need to fix the replication crisis in science.
Crowd sourced voting on which papers to test and prediction markets on what will replicate offers a potential path.
🧬 New funding opportunity now open on @ResearchHub: Next-Gen Human Enhancement — Muscle, Cognition, and Mood.
We're looking for high-impact research into compounds and strategies for human enhancement across three domains: muscle performance, cognitive function, and mood regulation.
💰$10,000 in seed funding for the best preregistered proposal. Open to PhD students, postdocs, and faculty worldwide.